Andere talen Orchestra BioMed Holdings, Inc.

Aandelen

OBIO

US68572M1062

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,71 ^USD	-4,85%		-7,65%	-48,41%

30/04	Orchestra BioMed Holdings, Inc. kondigt aan dat AVIM Therapy wereldwijd 110 octrooien heeft verworven	CI
27/03	Orchestra BioMed Holdings, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents	30/04
Orchestra BioMed Holdings, Inc. Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents	30/04
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024	30/04
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024	30/04
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update	27/03
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors	26/03
Orchestra BioMed Holdings, Inc. Announces Appointment of David Pacitti to Board of Directors	26/03
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting	13/03
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting	13/03
Orchestra Biomed Holdings, Inc. Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting	13/03
Orchestra BioMed to Participate in Upcoming Investor Conferences	07/03
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients	06/03
Orchestra Biomed Holdings, Inc. Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy in Hypertensive Pacemaker Patients	06/03
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years	26/02
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years	26/02
Orchestra Biomed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with Avim Therapy for over 3 Years	26/02
Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients	08/01
Orchestra Biomed Announces Initiation of Backbeat Pivotal Study of Avim Therapy in Hypertensive Pacemaker Patients	08/01
Earnings Flash (OBIO) ORCHESTRA BIOMED HOLDINGS Reports Q3 Revenue $419,000	13/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Orchestra BioMed Holdings, Inc.

Aandelen

OBIO

US68572M1062

Andere talen

Filters